UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2244-6
Program Prior Authorization/Medical Necessity
Medication Empaveli® (pegcetacoplan)
P&T Approval Date 7/2021, 7/2022, 8/2023, 2/2024, 4/2024, 4/2025
Effective Date 7/1/2025
1. Background
Empaveli (pegcetacoplan) is a complement inhibitor indicated for the treatment of adult
patients with paroxysmal nocturnal hemoglobinuria (PNH).
2. Coverage Criteriaa:
A. Initial Authorization
1. Empaveli will be approved based on all of the following criteria:
a. Submission of medical records (e.g., chart notes, laboratory values, etc.)
documenting the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) as
confirmed by both of the following:
(1) Flow cytometry analysis confirming presence of PNH clones
-AND-
(2) Laboratory results, signs, and/or symptoms attributed to PNH (e.g., abdominal
pain, anemia, dyspnea, extreme fatigue, smooth muscle dystonia,
unexplained/unusual thrombosis, hemolysis/hemoglobinuria, kidney disease,
pulmonary hypertension, etc.)
-AND-
b. One of the following:
(1) Patient will not be prescribed Empaveli in combination with another
complement inhibitor used for the treatment of PNH (e.g., Bkemv, Fabhalta,
PiaSky, Soliris, Ultomiris)
-OR-
(2) Patient is currently receiving another complement inhibitor (e.g., Bkemv,
Fabhalta, PiaSky, Soliris, Ultomiris) which will be discontinued and Empaveli
will be initiated in accordance with the United States Food and Drug
Administration approved labeling
-AND-
© 2025 UnitedHealthcare Services Inc.
1
c. Prescribed by, or in consultation with one of the following:
(1) Hematologist
(2) Oncologist
Authorization will be issued for 12 months.
B. Reauthorization
1. Empaveli will be approved based on all of the following criteria:
a. Documentation of positive clinical response to Empaveli therapy (e.g., increased or
stabilization of hemoglobin levels, reduction in transfusions, improvement in
hemolysis, decrease in LDH, increased reticulocyte count, etc.)
-AND-
b. Patient is not receiving Empaveli in combination with another complement inhibitor
used for the treatment of PNH (e.g., Bkemv, Fabhalta, PiaSky, Soliris, Ultomiris)
-AND-
c. Prescribed by, or in consultation with one of the following:
(1) Hematologist
(2) Oncologist
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Empaveli [package insert], Waltham, MA: Apellis Pharmaceuticals, Inc.; September 2023.
2. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal
hemoglobinuria. Blood. 2005 Dec 1; 106(12): 3699–3709.
3. Devalet B, Mullier F, Chatelain B, et al. Pathophysiology, diagnosis, and treatment of
paroxysmal nocturnal hemoglobinuria: a review. Eur J Haematol. 2015 Sep;95(3):190-8.
© 2025 UnitedHealthcare Services Inc.
2
4. Sutherland DR, Keeney M, Illingworth A. Practical guidelines for the high-sensitivity
detection and monitoring of paroxysmal nocturnal hemoglobinuria clones by flow
cytometry. Cytometry B Clin Cytom. 2012 Jul;82(4):195-208.
5. Röth A, Maciejewski J, Nishimura JI, et al. Screening and diagnostic clinical algorithm for
paroxysmal nocturnal hemoglobinuria: Expert consensus. Eur J Haematol. 2018
Jul;101(1):3-11.
Program Prior Authorization/Medical Necessity - Empaveli® (pegcetacoplan)
Change Control
7/2021 New program
7/2022 Annual review with no changes to coverage criteria. Updated citations
in background and coverage criteria.
8/2023 Annual review. Updated references.
2/2024 Added Fabhalta to list of examples of other complement inhibitors used
for the treatment of PNH. Revised initial authorization to 12 months.
Included criteria for therapeutic duplication. Updated references.
4/2024 Simplified criteria language for converting to new complement inhibitor
therapy.
4/2025 Annual review. No changes to coverage criteria. Updated examples of
alternate complement inhibitors.
© 2025 UnitedHealthcare Services Inc.
3